Literature DB >> 20845886

Tricuspid regurgitation in patients with severe mitral regurgitation and normal left ventricular ejection fraction: risk factors and prognostic implications in a cohort of 895 patients.

Padmini Varadarajan1, Ramdas G Pai.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Although tricuspid regurgitation (TR) is common in patients with mitral regurgitation (MR), its frequency, determinants and prognostic implications in those with severe MR and a normal left ventricular ejection fraction (LVEF) are not fully known. The study aim was to evaluate the risk factors for, and prognostic implications of, TR in patients with severe MR and a normal LVEF.
METHODS: In this retrospective cohort study, the authors' echocardiographic database for the period between 1993 and 2003 was screened for patients with severe MR and LVEF > or = 55%. Chart reviews were performed for clinical, pharmacological and surgical details, while survival was analyzed as a function of TR severity.
RESULTS: Among 895 patients with severe MR and normal LVEF, 510 (57%) had grade > or = 2+ TR, while 219 (24%) had grade 3 or 4+ TR. Those patients with grade > or = 2+ TR were older (p < 0.0001), more likely to be female (p < 0.0001), and had a higher right ventricular systolic pressure (RVSP) (p < 0.0001). After adjusting for group differences (except for atrial fibrillation), grade > or = 2+ TR was associated with a higher mortality (relative risk 1.4, 95% confidence interval 1.1-1.8, p = 0.02). Mitral valve surgery was associated with a better survival in those with grade > or = 2+TR (p = 0.0003).
CONCLUSION: Significant TR is a frequent occurrence in patients with severe MR and a normal LVEF, and is associated with older age, female gender, and a higher RVSP. TR is independently associated with a higher mortality, while mitral valve surgery seems to offer a survival benefit.

Entities:  

Mesh:

Year:  2010        PMID: 20845886

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  8 in total

1.  Assessment of tricuspid annulus: anatomic and echocardiographic correlation.

Authors:  Victor M Parra; Guillermina Fita; Jose Luis Pomar; Irene Rovira; Alain Berrebi; Marta Sitges
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-19       Impact factor: 2.357

Review 2.  Tricuspid surgery for tricuspid regurgitation: review.

Authors:  Tadashi Isomura; Yasuhisa Fukada; Takuya Miyazaki; Masahiro Endo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-06-27

3.  Prognostic implications of tricuspid regurgitation in patients with severe aortic regurgitation: results from a cohort of 756 patients.

Authors:  Padmini Varadarajan; Ramdas G Pai
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-17

Review 4.  Tricuspid Valve Percutaneous Therapies.

Authors:  Bhaskar Bhardwaj; Joaquin E Cigarroa; Firas Zahr
Journal:  Curr Cardiol Rep       Date:  2022-06-29       Impact factor: 3.955

5.  Right heart chamber geometry and tricuspid annulus morphology in patients undergoing mitral valve repair with and without tricuspid valve annuloplasty.

Authors:  Gloria Tamborini; Laura Fusini; Manuela Muratori; Paola Gripari; Sarah Ghulam Ali; Cesare Fiorentini; Mauro Pepi
Journal:  Int J Cardiovasc Imaging       Date:  2016-01-28       Impact factor: 2.357

6.  Heterotopic caval valve implantation for the management of severe tricuspid regurgitation: a case series.

Authors:  Aidan Sharkey; Ronny Munoz Acuna; Kiran Belani; Ravi K Sharma; Omar Chaudhary; Huma Fatima; Roger Laham; Feroze Mahmood
Journal:  Eur Heart J Case Rep       Date:  2020-12-28

7.  Outcome of consistent guideline-based tricuspid management in patients undergoing degenerative mitral regurgitation correction.

Authors:  Gilles D Dreyfus; Benjamin Essayagh; Giovanni Benfari; Filip Dulguerov; Shelley Rahman Haley; Carine Dommerc; Adelin Albert; Maurice Enriquez-Sarano
Journal:  JTCVS Open       Date:  2021-07-20

8.  Tricuspid Regurgitation - Medical Management and Evolving Interventional Concepts.

Authors:  Frederik Beckhoff; Brunilda Alushi; Christian Jung; Eliano Navarese; Marcus Franz; Daniel Kretzschmar; Bernhard Wernly; Michael Lichtenauer; Alexander Lauten
Journal:  Front Cardiovasc Med       Date:  2018-05-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.